Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus

Suprun O.: Donetsk Railroad Station Clinical Hospital

Bagriy A.: M. Gorky Donetsk National Medical University, Donetsk

Mykhailichenko E.: M. Gorky Donetsk National Medical University, Donetsk

Krivushcheva M.: M. Gorky Donetsk National Medical University, Donetsk

Download in PDF

Summary

An article reviews the use of glucagon-like peptide-1 (GLP-1) receptor agonists for treatment of patients with type 2 diabetes mellitus associated with high cardiovascular risk, chronic heart failure with low left ventricular ejection fraction and diabetic nephropathy. The authors discuss the mechanisms of action of GLP-1 receptor agonists, their main advantages (significant hypoglycemic effect, organoprotection and improved cardiovascular and renal outcomes) and dosedependent side effects.

Key words

Glucagon-like peptide-1 receptor agonists, coronary artery disease, chronic heart failure, diabetic nephropathy, intestinal diseases.